‘Significant Potential’: This ASX Stock Is Winning The Race To Make Cancer Care Heart-Safe
‘Significant Potential’: This ASX Stock Is Winning The Race To Make Cancer Care Heart-Safe
For all the excitement about curing cancer or the disease going into remission, the relief for some patients can often be short-lived if the treatment leaves them with other potentially long-term health repercussions. Cardiovascular...
Race Oncology (ASX: RAC) 2023 Annual General Meeting
Race Oncology (ASX: RAC) 2023 Annual General Meeting
The Race Oncology Annual General Meeting was held on Monday 27 November 2023. During the meeting the Race Board and management team provided an update on the forward-looking strategy, detailed new clinical development plans...
‘Strongly Positioned To Move The Business Forward’: Race Oncology Appoints New CEO
‘Strongly Positioned To Move The Business Forward’: Race Oncology Appoints New CEO
Clincal stage biopharmaceutical company Race Oncology (ASX:RAC) says Tillett will work alongside executive director Dr Pete Smith, to advance the company’s strategic, clinical and commercialisation plans for its core asset reformulated bisantrene, RC220. Read more here....
Race Appoints New CEO And Launches Updated Strategy
Race Appoints New CEO And Launches Updated Strategy
Race Oncology has announced that Dr Daniel Tillett has been appointed full-time Chief Executive Officer. Dr Tillett’s appointment is effective immediately and he will work alongside Executive Director, Dr Pete Smith, to advance Race’s...
Race Oncology To Present “Highly Positive” AML Clinical Trial Outcomes At American Society Of Hematology Annual Conference
Race Oncology To Present “Highly Positive” AML Clinical Trial Outcomes At American Society Of Hematology Annual Conference
Race Oncology Ltd (ASX:RAC) has fielded “impressive” Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial. The interim clinical results are from an ongoing investigator-initiated Phase 2 trial of bisantrene in...
Race Oncology Releases ‘Striking’ Interim Phase 2 AML Trial Results
Race Oncology Releases ‘Striking’ Interim Phase 2 AML Trial Results
Race Oncology (ASX:RAC) has announced positive interim clinical results from an ongoing investigator-initiated Phase II study of its core asset bisantrene in combination with fludarabine and clofarabine in R/R AML patients. Read more here....
Race Oncology Kicks Off Safety Studies For RC220
Race Oncology Kicks Off Safety Studies For RC220
Race Oncology Ltd (ASX:RAC) executive director Dr Pete Smith speaks with Proactive soon after announcing the company has initiated the toxicology and safety pharmacology studies required to support human clinical trials of its flagship bisantrene formulation for...
March 2023 Update
March 2023 Update
Race Oncology Limited (“Race”) announces Executive Director and Chief Scientific Officer (CSO), Dr Daniel Tillett has advised his decision to step down from his roles. Dr Tillett will provide ongoing support through June 2023...
December 2022 Update
December 2022 Update
Race is pleased to announce the appointment of global pharmaceutical and commercial leader, Mr Damian Clarke-Bruce, as Managing Director and Chief Executive Officer, effective 1 February 2023. Mr Phil Lynch will return to his...
